NCT03643380 is a Phase 1 clinical trial of AHLeveeS System in Overactive Bladder, sponsored by Neuspera Medical, Inc..

Who is sponsoring NCT03643380?

NCT03643380 is sponsored by Neuspera Medical, Inc..

What drugs are being tested in NCT03643380?

Interventions in NCT03643380: AHLeveeS System.

What condition does NCT03643380 study?

NCT03643380 studies Overactive Bladder.

Is NCT03643380 still recruiting?

NCT03643380 is currently completed. Last updated 22 August 2018.

Last reviewed 2018-08-22 · How we verify

NCT03643380

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acute Study to Evaluate a Novel Implantable Midfield Powered Device in Humans With Urinary Incontinence

Completed Phase 1 Last updated 22 August 2018

What this trial tests

Phase 1 trial testing AHLeveeS System in Overactive Bladder in 6 participants. Completed in 30 January 2018.

Timeline

17 August 2017

Primary endpoint
15 November 2017

30 January 2018

Quick facts

Lead sponsor	Neuspera Medical, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	device feasibility
Enrollment	6
Start date	17 August 2017
Primary completion	15 November 2017
Estimated completion	30 January 2018
Sites	1 location across Netherlands

Drugs / interventions tested

AHLeveeS System

Conditions studied

Overactive Bladder — all drugs for Overactive Bladder →

Sponsor

Neuspera Medical, Inc. — full company profile →

Who can join

Adults 18 to 65, any sex, with Overactive Bladder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A pre-market, prospective, non-randomized acute feasibility study for the treatment of patients with urinary incontinence (UI) as a consequence of urinary incontinence.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Overactive Bladder

Currently open trials in the same condition.

NCT06201013 — Vitamin D Treat-to-Target Strategy for Children With Overactive Bladder-Wet · NA · recruiting
NCT05895045 — Yoga for Treatment of Overactive Bladder in Pediatric Patients · NA · recruiting
NCT07209397 — Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women · NA · recruiting
NCT06921746 — Changes in the Urinary Microbiome and Metabolome During Treatment of the Overactive Bladder in Female Patients · recruiting
NCT06935240 — Investigation of Effects of Electrical Stimulation in Women With Vaginal Laxity · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03643380 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Neuspera Medical, Inc.
Last refreshed: 22 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03643380.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing